| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FOXL2 |
| Uniprot No | P58012 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-376aa |
| 氨基酸序列 | MMASYPEPEDAAGALLAPETGRTVKEPEGPPPSPGKGGGGGGGTAPEKPDPAQKPPYSYVALIAMAIRESAEKRLTLSGIYQYIIAKFPFYEKNKKGWQNSIRHNLSLNECFIKVPREGGGERKGNYWTLDPACEDMFEKGNYRRRRRMKRPFRPPPAHFQPGKGLFGAGGAAGGCGVAGAGADGYGYLAPPKYLQSGFLNNSWPLPQPPSPMPYASCQMAAAAAAAAAAAAAAGPGSPGAAAVVKGLAGPAASYGPYTRVQSMALPPGVVNSYNGLGGPPAAPPPPPHPHPHPHAHHLHAAAAPPPAPPHHGAAAPPPGQLSPASPATAAPPAPAPTSAPGLQFACARQPELAMMHCSYWDHDSKTGALHSRLDL |
| 预测分子量 | 43.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FOXL2重组蛋白的3篇代表性文献示例(注：文献信息为模拟概括，具体内容请以实际文献为准)：
---
1. **文献名称**：Functional characterization of recombinant FOXL2 protein in ovarian granulosa cell development
**作者**：Benayoun BA, et al.
**摘要**：研究通过重组FOXL2蛋白体外实验，揭示其通过结合靶基因启动子区域(如CYP19A1)调控颗粒细胞分化和雌激素合成的分子机制，并发现特定突变会导致DNA结合能力丧失。
---
2. **文献名称**：FOXL2 mutations induce apoptosis via recombinant protein expression in COV434 cells
**作者**：Kim JH, et al.
**摘要**：利用重组FOXL2野生型和突变型蛋白处理颗粒细胞，证明突变体通过干扰TGF-β信号通路促进细胞凋亡，为卵巢早衰(POI)的病理机制提供依据。
---
3. **文献名称**：Recombinant FOXL2 inhibits Wnt/β-catenin signaling by direct interaction with β-catenin
**作者**：Uhlenhaut NH, et al.
**摘要**：通过重组蛋白互作实验证实，FOXL2通过结合β-catenin抑制Wnt通路活性，维持卵巢颗粒细胞的正常增殖分化平衡，该功能的异常与卵巢颗粒细胞瘤发生相关。
---
建议通过PubMed或Google Scholar检索关键词“recombinant FOXL2 protein”获取真实文献。
**Background of FOXL2 Recombinant Protein**
FOXL2 is a member of the forkhead box (FOX) family of transcription factors, encoded by the *FOXL2* gene located on human chromosome 3q22.3. It plays a critical role in ovarian development, folliculogenesis, and maintenance of ovarian function, particularly in granulosa cells. Mutations in *FOXL2* are linked to blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES), a rare genetic disorder characterized by eyelid abnormalities and, in some cases, premature ovarian insufficiency (POI).
Recombinant FOXL2 protein is produced using biotechnological methods, such as expression in bacterial (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian or insect cells), followed by purification via affinity chromatography. This engineered protein retains the functional DNA-binding forkhead domain and transcriptional regulatory activity, enabling researchers to study its interactions with target genes (e.g., *CYP19A1*, involved in estrogen synthesis) and signaling pathways (e.g., TGF-β and apoptosis regulation).
FOXL2 recombinant protein is widely used to investigate ovarian biology, sex determination, and pathologies like granulosa cell tumors (GCTs), where somatic *FOXL2* mutations (e.g., C134W) are diagnostic markers. It also aids in developing therapeutic strategies for BPES and POI, as well as in vitro models to explore folliculogenesis and steroidogenesis. Challenges include ensuring proper post-translational modifications (e.g., phosphorylation) for functional studies and optimizing delivery mechanisms for potential clinical applications.
Overall, FOXL2 recombinant protein serves as a vital tool for unraveling reproductive biology and advancing treatments for related genetic and endocrine disorders.
×
